Baseline clinical and demographic characteristics of the first 19 children treated for MDR-TB in Lesotho, 2007–2011.

Note: PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis; Pos: positive; Neg: negative; H: isoniazid; R: rifampicin; E: ethambutol; S: streptomycin; Z: pyrazinamide; Eto: ethionamide; Cfx: ciprofloxacin; Cm: capreomycin; Km: kanamycin; Mfx: moxifloxacin; Ofx: ofloxacin; Lfx: levofloxacin; Cs: cycloserine; Pto: prothionamide; PAS: para-aminosalicylic acid.aThis patient was smear- and culture-positive before commencing first-line TB treatment but culture converted prior to initiating MDR-TB treatment.bPatients’ isolates were tested for resistance to H, R, E, S using BACTEC MGIT 960 system (Becton-Dickson, Sparks, Maryland, USA), unless otherwise indicated.cThis patient’s isolate was tested for resistance to H, R, E, S, Z using epsylometer test (Etest) on agar plate.dThese patients’ isolates were tested for resistance to H, R using line probe assay (Hain Lifescience GmbH, Nehren, Germany).eThis patient did not have baseline DST results but later had DST results from a positive culture in the tenth month of treatment.